Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Invivyd, Inc.

IVVD ✗ NOT COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$0.81

▼ -2.98%

Market Cap $237.37M · Vol 436.39K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$237.37M

Micro Cap

Div Yield

N/A

EPS Growth

-75.56%

YoY

RSI (14)

40.71

Momentum

Beta

0.97

vs Market

52W High

$3.05

73.60% below

52W Low

$0.53

52.58% above

Volume

436.39K

Avg 603.54K

P/B

2.88

Price-to-book

ROE

N/A

Return on equity

Free Float

86.50%

Public shares

Shariah Compliance8 STANDARDS

✗ Invivyd, Inc. (IVVD) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IVVD pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.00%

+11.71%

-9.70%

-51.78%

YTD

-67.40%

-36.09%

-53.98%

-98.56%

Financials & Valuation

TTM · Annual

Total Revenue	$53.43M
Net Income	$-52,489,000.00
Revenue Growth (YoY)	+21.20%
Gross Margin	92.99%
Operating Margin	-103.99%
Net Profit Margin	-98.25%
ROE	N/A
ROA · ROIC	-25.83% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	7.96
P/B	2.88
P/FCF	N/A
EPS Growth	-75.56%
Outstanding Shares	294.76M

Technical Indicators

50-Day SMA	$0.76
200-Day SMA	$1.44
RSI (14)	40.71
Beta	0.97
52-Week High	$3.05
52-Week Low	$0.53

Volume Today	436.39K
Avg Daily Volume (30D)	603.54K
Relative Volume	0.72x
Volatility (10D)	91.11
Volatility (30D)	103.53
Free Float	86.50%

Analyst Consensus

BUY

Current Price $0.81

Mean Target $10.00

52W Low$0.53 52W High$3.05

Current

Target

$0.53 $3.05

Current Analyst target

+1,141.77% upside potential · 3 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00W4ML048

ISINUS00534A1025

CountryUSA

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company +0.15% JNJ Johnson & Johnson +0.03% ABBV AbbVie Inc. -0.20% NVS Novartis AG +0.06% NOVN.S Novartis AG +0.39%

Company Profile

Invivyd, Inc. is a biopharmaceutical company. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.